Core Viewpoint - The article emphasizes the trend of "medical-research co-creation" in the domestic beauty industry, highlighting that while this concept is gaining traction, it is still in its infancy in China, lacking clear implementation standards. The German skincare brand Eucerin has set a precedent with its comprehensive approach to medical-research co-creation over its 125-year history [3][6]. Group 1: Eucerin's Achievements - Eucerin showcased its advancements at the 34th European Academy of Dermatology and Venereology (EADV) with three thematic satellite sessions and 18 academic posters, particularly highlighting the publication of the "International Consensus on Pigment Management," which includes the patented ingredient Thiamidol® in global treatment recommendations [4][24]. - Eucerin's practice serves as a practical guide for the Chinese beauty industry, demonstrating a successful model of medical-research co-creation [6][21]. - The brand has built a robust medical-research co-creation system, which is recognized as a competitive advantage, rooted in its unique scientific brand heritage established in 1900 [7][11]. Group 2: Research and Development - Eucerin has established a standard medical-research co-creation pathway consisting of clinical insights, product development, and efficacy evaluation, successfully navigating these core stages [12][16]. - The brand collaborates closely with thousands of dermatology experts globally and holds over 1,500 effective patents, investing more than €200 million annually in research and development [16][38]. - The efficacy of Thiamidol® has been validated through over 120 clinical studies involving more than 9,000 participants across 28 countries, proving its effectiveness for all skin types [16][29]. Group 3: Localization in China - Eucerin has effectively localized its medical-research co-creation model in China, launching the second-generation Eucerin Brightening Essence with dual certifications for "whitening" and "new ingredient registration" [19][40]. - The product development involved extensive collaboration with local dermatologists and consumer research, addressing the specific needs of Chinese consumers [19][42]. - Eucerin's innovative "Red-Brown-Black" pigment management strategy systematically addresses pigmentation issues, showcasing its commitment to localized solutions [19][21]. Group 4: Market Performance - The functional skincare market in China is rapidly growing, with the market size increasing from ¥7.42 billion in 2016 to ¥48 billion in 2024, indicating a competitive landscape [37]. - Eucerin achieved a remarkable 61.9% organic sales growth in the Chinese market in the first half of the year, significantly outperforming expectations [38][39]. - The brand's success is attributed to its comprehensive strategy, including expanding its target audience, localized R&D, entering the medical aesthetics sector, and enhancing brand communication [38][40][42]. Group 5: Academic Contributions - Eucerin's participation in the EADV conference included the release of the "International Consensus on Pigment Management," which provides a unified standard for diagnosing and treating common pigmentary disorders [27][30]. - The brand's focus on skin microbiome and anti-aging breakthroughs was highlighted in discussions led by global experts, emphasizing the importance of integrating skin science with clinical practice [30][31]. - Eucerin's product matrix, particularly its anti-pigment series, received significant attention, showcasing its commitment to evidence-based solutions in clinical and daily skincare [32][35]. Group 6: Future Outlook - Eucerin's trajectory from a German pharmacy to a prominent player on the international academic stage exemplifies the successful implementation of medical-research co-creation in the beauty industry [44]. - The brand's long-term commitment to research and development, combined with its strategic focus on the Chinese market, positions it to lead industry trends and innovations [44].